Inspire Investing LLC Has $356,000 Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Inspire Investing LLC increased its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 34.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,677 shares of the biotechnology company’s stock after buying an additional 13,908 shares during the quarter. Inspire Investing LLC’s holdings in Ironwood Pharmaceuticals were worth $356,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Old West Investment Management LLC lifted its position in shares of Ironwood Pharmaceuticals by 1.4% during the 4th quarter. Old West Investment Management LLC now owns 56,921 shares of the biotechnology company’s stock valued at $651,000 after acquiring an additional 761 shares during the period. Texas Permanent School Fund Corp lifted its position in Ironwood Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 120,245 shares of the biotechnology company’s stock worth $1,047,000 after purchasing an additional 1,557 shares during the period. CWM LLC lifted its position in Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the period. Louisiana State Employees Retirement System grew its stake in Ironwood Pharmaceuticals by 3.5% during the second quarter. Louisiana State Employees Retirement System now owns 70,400 shares of the biotechnology company’s stock worth $459,000 after buying an additional 2,400 shares in the last quarter. Finally, SummerHaven Investment Management LLC increased its holdings in Ironwood Pharmaceuticals by 3.6% in the 2nd quarter. SummerHaven Investment Management LLC now owns 72,030 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 2,491 shares during the period.

Insiders Place Their Bets

In related news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the transaction, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD opened at $4.30 on Friday. The company has a market cap of $673.07 million, a PE ratio of -0.63 and a beta of 0.49. The firm’s 50 day simple moving average is $5.34 and its 200 day simple moving average is $6.62. Ironwood Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $15.70.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wells Fargo & Company reduced their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Leerink Partners began coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price on the stock. Finally, Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.57.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.